Vaginal progesterone for the prevention of neonatal Respiratory Distress Syndrome - a randomised controlled trial

呼吸窘迫综合症是早产儿(怀孕不到34周)的一个重大问题。对于这些婴儿来说，超过90%的婴儿需要支持他们的呼吸。这些婴儿的死亡风险也增加了，对于幸存者来说，存在长期残疾的风险。目前还不确定在怀孕期间对有过早产经历的女性进行阴道孕酮治疗是否可以降低这些风险。这项随机对照试验将评估对有早产风险的妇女使用阴道孕酮疗法，作为降低新生儿呼吸窘迫综合征风险和改善其婴儿结局的一种手段。

Respiratory Distress Syndrome is a significant problem for babies born very preterm (at less than 34 weeks of pregnancy). For these babies, over 90% will require support for their breathing. These babies are also at increased risk of dying, and in survivors, there is a risk of long-term disability. It is uncertain if giving vaginal progesterone therapy during pregnancy to women who have had a previous preterm birth can reduce these risks. This randomised controlled trial will assess the use of vaginal progesterone therapy for women at risk of preterm birth as a means of reducing the risk of neonatal Respiratory Distress Syndrome and improving the outcomes of their babies.